作者
José M Ferro, Jonathan M Coutinho, Francesco Dentali, Adam Kobayashi, Andrey Alasheev, Patrícia Canhão, Denis Karpov, Simon Nagel, Laura Posthuma, José Mário Roriz, Jorge Caria, Mandy Frässdorf, Holger Huisman, Paul Reilly, Hans-Christoph Diener, RE-SPECT CVT Study Group
发表日期
2019/12/1
期刊
JAMA neurology
卷号
76
期号
12
页码范围
1457-1465
出版商
American Medical Association
简介
Importance
Patients with cerebral venous thrombosis (CVT) are at risk of recurrent venous thrombotic events (VTEs). Non–vitamin K oral anticoagulants have not been evaluated in randomized controlled trials in CVT.
Objective
To compare the efficacy and safety of dabigatran etexilate with those of dose-adjusted warfarin in preventing recurrent VTEs in patients who have experienced a CVT.
Design, Setting, and Participants
RE-SPECT CVT is an exploratory, prospective, randomized (1:1), parallel-group, open-label, multicenter clinical trial with blinded end-point adjudication (PROBE design). It was performed from December 21, 2016, to June 22, 2018, with a follow-up of 25 weeks, at 51 tertiary sites in 9 countries (France, Germany, India, Italy, the Netherlands, Poland, Portugal, Russia, and Spain). Adult consecutive patients with acute CVT, who were stable after 5 to 15 days of treatment with parenteral heparin, were …
学术搜索中的文章
JM Ferro, JM Coutinho, F Dentali, A Kobayashi… - JAMA neurology, 2019